Sydnexis is focused on addressing myopic progression in children through its innovative and patented formulation designed for comfort and efficacy. The company has developed a novel topical eyedrop, administered once daily at bedtime, which aims to effectively treat myopia. This formulation is currently being evaluated in the STAR Study, a pivotal Phase 3 clinical trial that involves over 850 children aged 3 to 14. The study is designed as a multi-center, randomized, double-masked, placebo-controlled trial to assess the efficacy of two dosage strengths of SYD-101 in slowing the progression of myopia.

In addition to its clinical efforts, Sydnexis emphasizes the importance of understanding myopia and its treatment options for patients. The company is committed to advancing research in this area and has a dedicated pipeline for ongoing studies. With a focus on both scientific innovation and patient education, Sydnexis aims to make significant contributions to the field of ophthalmology, particularly in the management of myopia in children.

United States

Sydnexis - Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD-101, in a Phase 3 clinical trial to decrease myopia progression in children.

Sydnexis

Company Details